|
KMID : 1040620220280030380
|
|
Clinical and Molecular Hepatology
2022 Volume.28 No. 3 p.380 ~ p.395
|
|
|
Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?
|
|
Goh Myung-Ji
Sinn Dong-Hyun
|
|
|
Abstract
|
|
|
|
Preclinical studies highlighted potential therapeutic applications of aspirin and statins as anticancer agents based on their pleiotropic effects. Epidemiologic studies suggested the role of aspirin and statins in the chemoprevention of hepatocellular carcinoma (HCC). However, observational data is prone to bias, and no prospective randomized trials are currently available to assess the risks and benefits of statin or aspirin therapy for chemoprevention of HCC. It is therefore important for clinicians and researchers to be aware of the quality of current evidence regarding this issue. In this review, we summarize currently available evidence to assist clinicians with their decision to use statin or aspirin and provide information for further clinical investigations.
|
|
|
KEYWORD
|
|
|
Statins, Aspirin, Hepatocellular carcinoma, Chemoprevention
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|